GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Does a Risk Class Predict Treatment Success?

No, not by itself. In Japan’s regenerative medicine system, Class I, II, or III is a risk category, not a treatment-success rating. Class I does not mean the best results, and Class III does not guarantee safety or benefit. To judge a treatment’s chance of helping, you need human evidence for the exact intervention and condition. MHLW’s 6,743 treatment plans on file as of 30 June 2026 are filings, not successful treatments 001590173.pdf4980.

This article concerns Japan’s Act on the Safety of Regenerative Medicine (Act No. 85 of 2013), not disease-specific prognostic risk scores. Under this law, the class determines the oversight route; it does not rank treatments by effectiveness 4980.

Does a Risk Class Predict Treatment Success?

What a risk class tells you

  • Class I is the highest-concern group. Effects on life and health are unclear, or serious harm remains possible even with careful work. This group includes embryonic stem cells, iPS cells, gene-modified cells, certain donor-cell procedures and, since 31 May 2025, covered gene therapies put directly into the body 4980.
  • Class II is the middle group. Health risks remain possible with careful work, but the technique falls outside Class I. Many treatments that grow a patient’s own cells in the laboratory fall into this group 4980.
  • Class III covers the rest under the law. It includes techniques that are neither Class I nor Class II. Certain platelet-rich plasma (PRP) applications are one example 4980.

The class determines the type of committee review required. Class I plans also face national-level review and a waiting period, normally 90 days, which MHLW can shorten or extend Plan. More intensive oversight is not evidence of greater benefit.

Do more plans in a class mean better results?

No. MHLW’s report counted 6,743 treatment plans and 85 research plans as of 30 June 2026. The table below shows the distribution of treatment filings. It does not show how many patients improved, how long benefits lasted, or how many had complications. The largest group, Class III, therefore cannot be called the most effective on the basis of these counts 001590173.pdf.

Japan snapshot (dated figures, not live totals) Value Date and source
Treatment plans on file 6,743, plus 85 research plans 30 June 2026 001590173.pdf
Class I / II / III share of treatment plans 8 (0.1%) / 2,463 (36.5%) / 4,272 (63.4%) Same report 001590173.pdf
Approved regenerative products 26 active (28 cumulative minus one withdrawal and one expiry) 20 May 2026, PMDA 000280868.pdf

Why paperwork does not predict outcomes

A filing, a product approval, and a trial registration answer different questions:

  1. A filed provision plan means a clinic completed the Safety Act filing and committee review. The filing alone does not approve a product, and it does not show the treatment works Plan.
  2. A marketed product approval follows a separate law. In Japan, PMDA examines the science and the MHLW Minister gives approval under the Pharmaceuticals and Medical Devices Act. PMDA’s presentation dated 20 May 2026 reported 26 products with active approval, including gene therapies and cell- and tissue-based products. These are named products with stated uses and conditions, not approvals of private-clinic treatment menus 000280868.pdf.

    The U.S. FDA’s approval of Ryoncil (remestemcel-L-rknd) illustrates how specific an approval is. This donor bone-marrow-derived mesenchymal stromal cell (MSC) therapy is given by intravenous infusion for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. A multicenter, single-arm study included 54 children. At day 28, 16 (30%) had a complete response and 22 (41%) had a partial response. Common adverse reactions included infections, fever, bleeding, swelling, abdominal pain, and high blood pressure Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.

    A day-28 response is not a long-term cure rate. With no concurrent comparison group, the study does not provide a randomized estimate of benefit over another treatment. Its findings do not establish effectiveness for other MSC preparations or diseases Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.

  3. A trial registration only shows that a study record exists in a system such as Japan’s jRCT En top. A registration is not a result. Listing in a literature database also does not tell you whether the study was well done.

In checking the documents for this article, we compared the MHLW snapshot dated 30 June 2026 with PMDA’s presentation dated 20 May 2026. The first counts provision plans; the second counts approved products. Dividing 26 products by 6,743 plans would not give an approval rate or a patient’s chance of benefit: the units, legal routes, and dates differ 001590173.pdf000280868.pdf. This is a document-checking observation, not experience treating patients. The site’s registration-and-compliance overview explains the distinction between plan filing and product approval.

What evidence helps assess the chance of benefit?

First agree on what “success” means for the condition being treated: which outcome, how much improvement, and at what follow-up time. Then check these four areas:

  • Your diagnosis, stage, and history. The same cells may have different evidence for different diseases. Age, disease stage, other illnesses, and current drugs can each change the likely benefit and the risk.
  • The exact treatment. Check the cell source, cell type, dose, number of sessions, administration route, and cell-processing arrangements. Two treatments with a similar cell name can still differ. Approval of one product does not extend to a clinic preparation with a similar name 000280868.pdf.
  • Human studies of that exact use. Ask which trials tested this use, who took part, how many people were included, whether there was a comparison group, and what was measured. Animal or laboratory findings do not establish benefit in humans. Patient stories and before-and-after photos alone cannot establish that a treatment caused improvement.
  • Lasting effect and reported harms. Ask whether the effect lasted and which side effects were recorded. The U.S. FDA warns of safety concerns with unapproved regenerative products, including infections, unwanted immune or inflammatory reactions, tumors, and tissue growth in the wrong place. That guidance does not provide complication rates for Japan’s risk classes Important patient and consumer information about regenerative medicine therapies. The site’s discussion of safety in Japan provides local regulatory context, not a substitute for treatment-specific risk information. For U.S. product authorization, the FDA’s licensed-products list names RYONCIL as an individual entry; it does not authorize other treatments simply because they also use MSCs Approved cellular and gene therapy products.

Questions to ask before deciding

Bring these to the consult:

  • What is the exact diagnosis and stage this plan covers, and do I meet its eligibility criteria?
  • What are the cell source, processing method, dose, route, and session schedule in the current plan, and do the quote and consent documents describe the same intervention?
  • Which committee reviewed this plan, and can I see the current plan, consent materials, and any amendments?
  • What human evidence supports this exact use, including study phase, participant numbers, comparator, endpoints, follow-up, and adverse events? If a success rate is quoted, how was success defined, and how many treated patients were included or lost to follow-up?
  • Who assesses me, performs the procedure, and manages complications, and what follow-up is arranged?

The treatment-process walkthrough on this site places these documents in order, from the first consult to follow-up.

If you are weighing Class I, II, or III in Japan, bring your diagnosis and current prescriptions to the consult so the doctor can check eligibility against the filed plan.

Contact the clinic

The bottom line

A Japanese regenerative medicine risk class alone cannot tell you your chance of treatment success. The 6,743 treatment plans recorded on 30 June 2026 are not an outcomes dataset. Ask instead for results and harms for the exact treatment in patients with your condition, and discuss alternatives with a qualified doctor before deciding 001590173.pdf4980.

This article is general information about Japan’s regulatory framework, not personal medical advice. Figures are dated snapshots for Japan as stated, except where the U.S. is noted. Regulatory filing, product approval, and trial registration are different categories; none of them guarantees an individual result.